Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12190397 | 1.00 | HRH3 (0.34) | HRH3 | |
| SCHEMBL15126594 | 0.97 | HRH3 (0.35) | HRH3 | |
| Carbamic Acid SCHEMBL30694682 | 0.87 | — | — | |
| SCHEMBL1753765 | 0.86 | HRH3 (0.39) | HRH3 | |
| SCHEMBL19164021 | 0.86 | HRH3 (0.39) | HRH3 | |
| SCHEMBL15223081 | 0.86 | HRH3 (0.39) | HRH3 | |
| SCHEMBL26016464 | 0.86 | HRH3 (0.39) | HRH3 | |
| SCHEMBL26254285 | 0.86 | HRH3 (0.39) | HRH3 | |
| SCHEMBL26254694 | 0.86 | HRH3 (0.39) | HRH3 | |
| SCHEMBL1753965 | 0.86 | HRH3 (0.39) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | KI PHARMACEUTICALS, LLC | 2021-08-19 | — | — | US | disclosed |
| US-20200277449-A1 | INJECTABLE HYBRID ALGINATE HYDROGELS AND USES THEREOF | UNIV STRASBOURG (FR) | 2020-09-03 | — | — | US | disclosed |
| US-20200138711-A1 | INJECTABLE HYDROGELS AND USES THEREOF | IHU STRASBOURG INSTITUT HOSPITALO-UNIVERSITAIRE DE STRASBOURG (FR) | 2020-05-07 | — | — | US | disclosed |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20170266302-A1 | Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate | R.P. SCHERER TECHNOLOGIES, LLC | 2017-09-21 | — | — | US | disclosed |
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2016-02-11 | — | — | US | disclosed |
| US-8163791-B2 | Imidazole derivatives that induce apoptosis and their therapeutic uses | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2012-04-24 | — | — | US | disclosed |
| US-7888118-B2 | induces differentiation of myoblasts or muscle fiber into neuron cells; drug screening; useful for treatment of neurodegenerative disorders, such as stroke, spinal cord injury, Parkinson's and Alzheimer's diseases; 2-{2-[5-(3-chlorophenyl)]furanyl}-4,5-bis(4-methoxyphenyl)imidazole (Neurodazine 1) | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2011-02-15 | — | — | US | disclosed |
| US-20100184097-A1 | 4,5-BIS(4-METHOXYPHENYL)IMIDAZOLE COMPOUND INDUCING DIFFERENTIATION OF MYOBLASTS OR MUSCLE FIBERS INTO NEURON CELLS, A PHARMACEUTICAL COMPOSITION INCLUDING SAID COMPOUND, A METHOD OF INDUCING NEURON CELLS DIFFERENTIATION AND A SCREENING METHOD FOR IDENTIFYING ADDITIONAL COMPOUND USEFUL FOR INDUCING NEURON CELLS DIFFERENTIATION | INDUSTRY-ACADEMIC CORPORATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2010-07-22 | — | — | US | disclosed |
| US-7718685-B2 | 4,5-bis(4-methoxyphenyl)imidizole compound inducing differentiation of myoblasts or muscle fibers and pharmaceutical compositions including said compound | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2010-05-18 | — | — | US | disclosed |
| US-20100105726-A1 | IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2010-04-29 | — | — | US | disclosed |
| US-20070123576-A1 | Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | HRH3 3690/4885 |
| US-20230183209-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | HRH3 3844/4885 |
| US-20100105726-A1 | IMIDAZOLE DERIVATIVES THAT INDUCE APOPTOSIS AND THEIR THERAPEUTIC USES | NFATC1, AIFM1, TP53 | HRH3 4289/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | HRH3 2941/4885 |
| US-20180072711-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | HRH3 832/4885 |
| US-20200138711-A1 | INJECTABLE HYDROGELS AND USES THEREOF | CUTA, CD44, PLOD3 | HRH3 1264/4885 |
| US-20070123576-A1 | Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation | TNNC1, TNNI3, PYGM | HRH3 4129/4885 |
| US-20200277449-A1 | INJECTABLE HYBRID ALGINATE HYDROGELS AND USES THEREOF | SI, ALPI, PIGS | HRH3 596/4885 |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | HRH3 3355/4885 |
| US-20100184097-A1 | 4,5-BIS(4-METHOXYPHENYL)IMIDAZOLE COMPOUND INDUCING DIFFERENTIATION OF MYOBLASTS OR MUSCLE FIBERS INTO NEURON CELLS, A PHARMACEUTICAL COMPOSITION INCLUDING SAID COMPOUND, A METHOD OF INDUCING NEURON CELLS DIFFERENTIATION AND A SCREENING METHOD FOR IDENTIFYING ADDITIONAL COMPOUND USEFUL FOR INDUCING NEURON CELLS DIFFERENTIATION | MUSK, TNNI3, TNNC1 | HRH3 3474/4885 |
| US-20170266302-A1 | Hydrazinyl-Substituted Heteroaryl Compounds and Methods for Producing a Conjugate | HNMT, TIAL1, HACL2 | HRH3 308/4885 |
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | CYP19A1, PGR, CYP21A2 | HRH3 3516/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | HRH3 3565/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | HRH3 3219/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | HRH3 3219/4885 |
| US-20180215731-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | HRH3 3844/4885 |
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | HRH3 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.